The investment thesis on TG Therapeutics is that Briumvi is a more efficient and convenient version of the industry-leading drugs, allowing a small company to disrupt a $25 billion market dominated by Roche and Novartis. Briumvi offers a one-hour infusion twice a year, which is significantly faster than its main competitors and highly attractive to both patients and the private clinics that administer the drug. If TG Therapeutics can maintain this commercial momentum while expanding into new diseases, the stock is likely valued far below its long-term potential.
TG Therapeutics stock stayed flat for a long time but has soared lately. The price jumped because the company announced very successful early results for a new way to give its main drug to patients. Investors are excited that this treatment could soon help many more people, leading to a much better outlook for the business.
What does it do?
TG Therapeutics is a growth-stage biotech company that earns money by selling a specialized immune-system therapy called Briumvi. The company operates in the multiple sclerosis (MS) market, where patients require regular treatments to prevent their immune systems from attacking their own nerves. Briumvi is an "anti-CD20" monoclonal antibody, a type of protein designed to seek out and clear specific B-cells that cause inflammation. TG Therapeutics manufactures the drug and sells it primarily to specialty pharmacies and infusion centers, which then administer it to patients. The company’s primary edge is efficiency: while competing drugs can take hours to infuse, Briumvi requires only a one-hour session every six months.
Where does revenue come from?
Almost all revenue comes from net product sales of Briumvi in the United States. For the first quarter of 2026, U.S. Briumvi sales reached $194.8 million, representing over 96% of the company's total revenue. The remaining income is generated through sales to international partners and occasional milestone payments from licensing agreements. Geographically, the United States is the dominant market, though the company earns royalties and supply revenue from its partner, Neuraxpharm, in Europe.
Revenue Breakdown
Revenue by Geography
Who are its customers?
TG Therapeutics serves thousands of multiple sclerosis patients through a network of neurologists and private infusion clinics. In the first quarter of 2026, the company reported record new patient starts, and it currently captures a leading share of "dynamic" or new prescriptions in private practices with their own infusion capabilities. Because Briumvi is administered by a healthcare professional, the company's true customers are the neurologists who prescribe the drug and the clinics that profit from the operational simplicity of a one-hour infusion. While the company does not disclose a total cumulative patient count, its $201.3 million in quarterly revenue and 68% year-over-year growth indicate a rapidly expanding base of regular, repeat patients.
What gives it staying power?
TG Therapeutics is protected by a combination of strong patents and the high switching costs inherent in multiple sclerosis treatment. The company holds patents on its core technology that extend through 2044, preventing rivals from launching generic versions. Furthermore, once a patient starts on a high-efficacy therapy like Briumvi and sees stabilized symptoms, they and their doctors are highly reluctant to switch to a different drug.
Where is it headed?
The company is currently focused on moving Briumvi beyond the infusion clinic and into the patient's home. Management's biggest strategic bet is the development of a subcutaneous (under-the-skin) version of the drug that patients can inject themselves. This would allow TG Therapeutics to compete for the roughly 35% of the market that prefers self-administration over clinical visits. Additionally, the company is testing the drug for other diseases, such as myasthenia gravis, to multiply the number of patients it can serve.
Revenue growth has hit a major acceleration point as Briumvi scales toward a $1 billion annual run rate. Total revenue grew 68% year-over-year to $201.3 million in the latest quarter, far outpacing the biotech industry average. This momentum is driven by "record new patient starts," suggesting the drug is still early in its adoption curve.
The business has successfully reached cash flow sustainability, ending its reliance on outside funding. While free cash flow was slightly negative at -$20 million in 2025, the sharp rise in 2026 revenue is turning the company into a cash generator. This shift is critical because it allows the company to fund new clinical trials for other diseases using its own profits rather than issuing new shares.
TG Therapeutics maintains a healthy balance sheet with a substantial cash cushion to support its expansion. The company holds approximately $825 million in cash and has reached a stage where its quarterly revenue now exceeds its operating expenses. This net cash position provides the flexibility to invest in its "Azer-Cel" partnership for progressive MS without endangering the core business.
TG Therapeutics is now a high-margin, profitable commercial business with a clear path to multi-billion dollar scale.
Briumvi is winning the "convenience war" in neurology, with U.S. sales hitting a record $194.8 million last quarter. Doctors are increasingly choosing Briumvi because its one-hour infusion time allows clinics to treat more patients per day than competing drugs.
Competition from Novartis and Roche is intensifying as they defend their $20 billion collective market share. If these giants aggressively lower their prices or launch more convenient self-injectable versions first, it could slow TG Therapeutics' ability to win over the 35% of patients who prefer home treatment.
The multiple sclerosis (MS) drug market is a massive $25 billion global industry that grows at roughly 5% annually, but the "high-efficacy" segment within it is growing much faster as doctors shift away from older, less effective treatments. The industry is currently dominated by a few global giants, and pricing power is strong because these treatments are essential, life-long medications. The market is on track to exceed $30 billion by 2029 as newer, more convenient biologics replace older daily pills. TG Therapeutics is a disruptive challenger in this mature market, using a faster, more clinics-friendly infusion to win share from established players.
The multiple sclerosis market is intensely competitive, but it is structured as a "rational" battle between a few major brands with high barriers to entry. Developing a competing drug requires billions in research and years of clinical trials, which prevents new startups from easily entering. Long-term pricing power is protected by the high clinical stakes and the tendency for doctors to stick with proven brands.
Roche is the most dangerous threat because its drug, Ocrevus, is the current standard of care and has the deepest reach into neurology offices. Novartis also poses a significant risk with Kesimpta, which offers the convenience of home injection that Briumvi currently lacks. Novartis and Roche have significantly more marketing muscle and could use their scale to squeeze TG Therapeutics' distribution.
TG Therapeutics is currently the fastest-growing player in the high-efficacy MS segment, as evidenced by its 68% revenue jump last quarter. It is successfully winning share by offering a more efficient alternative to Roche's infusion.
The primary source of protection for TG Therapeutics is its strong intellectual property (IP) and patents that prevent rivals from copying Briumvi. The drug is protected by patents that extend as far as 2044, providing a decades-long runway to generate profits without generic competition. Because it is a complex biologic drug, it is much harder to replicate than a simple pill, adding an extra layer of structural protection.
The company's 83% gross margins and 68% revenue growth prove that it has a real, though narrow, competitive edge. These numbers show that TG Therapeutics can command high prices and win new customers even while competing against companies 50 times its size. This is not just a lucky cycle: it is the result of a product that is objectively more efficient for the clinics that administer it.
The moat is currently strengthening as the company builds a larger "installed base" of patients who are unlikely to switch. The single most important signal will be the successful launch of a subcutaneous version, which would broaden the moat to cover the entire MS market.
Beat and raised full-year 2026 revenue guidance to $925 million.
Reached GAAP profitability while maintaining over $800M in cash.
Founder CEO with a substantial personal stake and incentives tied to growth.
Capital Allocation Track Record
Michael S. Weiss has demonstrated exceptional strategic judgment by transitioning TG Therapeutics from a struggling research lab into a highly profitable commercial powerhouse. He successfully navigated the difficult launch of Briumvi during a period of high interest rates, choosing to partner for international rights rather than diluting shareholders with excessive stock sales. Management’s ability to "beat and raise" guidance consistently over the last four quarters has built significant credibility with investors, proving they can execute a "David vs. Goliath" strategy against much larger pharmaceutical firms.
The primary governance risk is the high degree of dependence on Weiss, who serves as Chairman, CEO, and President. While the commercial bench is strong, the company's long-term vision and aggressive competitive stance are deeply tied to his leadership. However, the Board of Directors is independent and has effectively overseen a shift toward disciplined spending, with the company now sitting on a massive $825 million cash cushion that provides a high degree of safety even if management needs to pivot.
The market is leaning bullish because the rapid expansion of Briumvi into new treatment areas is accelerating revenue growth. Positive phase one data for the subcutaneous version of Briumvi proves the drug can effectively treat conditions like myasthenia gravis, creating a significant new market beyond its current use in multiple sclerosis.
Skeptics think that the stock price has already climbed too far, leaving almost no room for any future trial disappointments. After the recent seventy percent surge, the current valuation assumes every future clinical milestone will succeed perfectly, meaning any minor setback in the upcoming phase two trials could trigger a sharp price drop.
We expect revenue to grow from $0.9B in FY2026 to $2.9B in FY2031 (~25% CAGR), with EPS growing from $1.38 to $6.80 (~38% CAGR). Briumvi is gaining market share in the multiple sclerosis market as a high-efficacy alternative to established treatments. Fixed research and commercialization costs are being spread across a larger revenue base as the drug launch scales. EPS grows faster than revenue because profit margins are expanding as the company moves past its initial heavy launch spending. Operating margin expected to reach ~35% by FY2031.
Launch of subcutaneous Briumvi captures self-injectable market. If the self-administered version is approved, TG Therapeutics can compete for the 35% of patients who currently choose Novartis for home treatment.
Expansion into Myasthenia Gravis doubles addressable market. Positive clinical data in MG would allow the company to sell the same drug to an entirely new patient population with high unmet need.
Global royalty stream from Neuraxpharm scales with zero cost. As the European partner launches Briumvi across more countries, TGTX collects pure-profit royalties that drop straight to the bottom line.
Large competitors use aggressive rebates to block clinic access. Roche or Novartis could use their massive scale to offer deep discounts to clinics that agree to stop prescribing Briumvi.
New class of oral "BTK inhibitors" disrupts the injectable market. If Sanofi or others successfully launch highly effective pills for MS, patients may abandon infusions and injections entirely.
Clinical trial failure for subcutaneous version or new indications. If the self-injected version fails to show the same efficacy as the infusion, the company's growth runway would be severely capped.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to future earnings) to determine the fair value. It fits TG Therapeutics because the company has recently reached sustained GAAP profitability, making earnings a cleaner and more reliable signal of value than the revenue multiples used for earlier-stage, loss-making biotech companies.
Our calculation applies a 30x multiple to the FY2027 EPS estimate of $2.53, resulting in a fair value of $76. A 30x multiple sits at the top end of the mature biotech range (Vertex 28x, Regeneron 20x, Biogen 13x) but is justified by TG’s much faster growth profile and the upcoming catalyst of the subcutaneous launch. We use the FY2027 EPS of $2.53 from the deterministic engine as our basis because it represents a more normalized year of commercial ramp-up than the current transition year.
A cross-check using EV/Revenue (FY2027 estimated revenue of $1.1B × 7x multiple) yields a fair value of $74, which is within 3% of our P/E-based answer. This confirmation suggests that both the top-line growth and the bottom-line profitability support a valuation in the mid-70s. The 7x revenue multiple is consistent with commercial-stage biotechs growing revenue at 30% or more annually, providing a high degree of confidence in the $76 target.
We're assuming BRIUMVI market share in the U.S. Relapsing Multiple Sclerosis (RMS) market reaches 15% by 2028. Current adoption is surging due to the drug’s one-hour infusion time, which is the fastest in its class and offers a significant operational advantage for private neurology clinics compared to Roche’s Ocrevus.
We're assuming the subcutaneous version of BRIUMVI receives FDA approval by late 2027. Phase 1 data released in early 2026 was positive, and the transition to a quick-injection format is critical for TG to compete in the "at-home" segment of the market, where convenience is the primary driver of patient choice.
We're assuming TG Therapeutics maintains its lean commercial structure even as revenue scales toward $1 billion. The company has demonstrated unusual operating leverage for a biotech, keeping sales and administrative costs low relative to peers, which supports our projection of net margins remaining above 40% as the product ramp matures.
The biggest risk is a competitive pricing war or aggressive pharmacy benefit manager (PBM) contracting that erodes Briumvi's net realized price. This would compress TG's high net margins and likely force the forward multiple down from 30x to 18x, knocking roughly $30 off our per-share fair value. Investors should watch "Gross-to-Net" adjustments in the quarterly filings for signs of margin pressure.
Bear case ($45): Briumvi U.S. revenue growth slows below 15% YoY as competitors Roche and Novartis launch aggressive price-matching programs; or The FDA issues a complete response letter (rejection) for the subcutaneous version of Briumvi, forcing a multi-year clinical delay.
Bull case ($115): Subcutaneous Briumvi receives early FDA approval and captures 30% of the at-home multiple sclerosis market by 2028; or Positive Phase 2 data in Myasthenia Gravis triggers a major partnership or acquisition rumor at a significant premium.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.